Seminars in Nephrology
Volume 29, Issue 4 , Pages 412-424 , July 2009

Progression of Glomerular and Tubular Disease in Pediatrics

  • Robert P. Woroniecki, MD

      Affiliations

    • Division of Nephrology, Department of Pediatrics, Albert Einstein College of Medicine, The Children's Hospital at Montefiore, Bronx, NY
    • Corresponding Author InformationAddress reprint requests to Robert P. Woroniecki, MD, The Children's Hospital at Montefiore, 3326 Bainbridge Ave, Bronx, NY 10467
    • ,
  • H. William Schnaper, MD

      Affiliations

    • Division of Kidney Diseases, Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL

References 

  1. Goldstein SL, Devarajan P. Progression from acute kidney injury to chronic kidney disease: a pediatric perspective. Adv Chronic Kidney Dis. 2008;15:278–283
  2. Schwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic kidney disease. Pediatr Nephrol. 2007;22:1839–1848
  3. Schainuck LI, Striker GE, Cutler RE, Benditt EP. Structural-functional correlations in renal disease (II. The correlations). Hum Pathol. 1970;1:631–641
  4. Seikaly MG, Ho PL, Emmett L, Fine RN, Tejani A. Chronic renal insufficiency in children: the 2001 Annual Report of the NAPRTCS. Pediatr Nephrol. 2003;18:796–804
  5. Barker DJ, Forsen T, Eriksson JG, Osmond C. Growth and living conditions in childhood and hypertension in adult life: a longitudinal study. J Hypertens. 2002;20:1951–1956
  6. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int. 2005;67:404–419
  7. Churg J, Habib R, White RH. Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. Lancet. 1970;760:1299–1302
  8. Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int. 2007;71:1205–1214
  9. Gudehithlu KP, Pegoraro AA, Dunea G, Arruda JA, Singh AK. Degradation of albumin by the renal proximal tubule cells and the subsequent fate of its fragments. Kidney Int. 2004;65:2113–2122
  10. Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest. 1995;96:953–964
  11. Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol. 2003;14:2618–2622
  12. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int. 1989;35:654–660
  13. Mori T, Polichnowski A, Glocka P, Kaldunski M, Ohsaki Y, Liang M, et al. High perfusion pressure accelerates renal injury in salt-sensitive hypertension. J Am Soc Nephrol. 2008;19:1472–1482
  14. Schernthaner G. Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy?. Nat Clin Pract Nephrol. 2008;4(12):656–657
  15. Chen S, Ge Y, Si J, Rifai A, Dworkin LD, Gong R. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int. 2008;74:1128–1138
  16. Zent R, Yan X, Su Y, Hudson BG, Borza DB, Moeckel GW, et al. Glomerular injury is exacerbated in diabetic integrin alpha1-null mice. Kidney Int. 2006;70:460–470
  17. Hayashida T, Wu MH, Pierce A, Poncelet AC, Varga J, Schnaper HW. MAP-kinase activity necessary for TGFbeta1-stimulated mesangial cell type I collagen expression requires adhesion-dependent phosphorylation of FAK tyrosine 397. J Cell Sci. 2007;120:4230–4240
  18. Nangaku M. Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Nephron Exp Nephrol. 2004;98:e8–e12
  19. Goligorsky MS. Frontiers in nephrology: viewing the kidney through the heart--endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2007;18:2833–2835
  20. Higgins DF, Kimura K, Iwano M, Haase VH. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle. 2008;7:1128–1132
  21. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis. 2006;47:42–50
  22. Chevalier RL, Forbes MS. Generation and evolution of atubular glomeruli in the progression of renal disorders. J Am Soc Nephrol. 2008;19:197–206
  23. Yoshida H, Kon V, Ichikawa I. Polymorphisms of the renin-angiotensin system genes in progressive renal diseases. Kidney Int. 1996;50:732–744
  24. Boonstra A, de Zeeuw D, de Jong PE, Navis G. Role of genetic variability in the renin-angiotensin system in diabetic and nondiabetic renal disease. Semin Nephrol. 2001;21:580–592
  25. Hunley TE, Julian BA, Phillips JA, Summar ML, Yoshida H, Horn RG, et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int. 1996;49:571–577
  26. August P, Leventhal B, Suthanthiran M. Hypertension-induced organ damage in African Americans: transforming growth factor-beta(1) excess as a mechanism for increased prevalence. Curr Hypertens Rep. 2000;2:184–191
  27. Pavkov ME, Knowler WC, Hanson RL, Bennett PH, Nelson RG. Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes. Am J Kidney Dis. 2008;51:759–766
  28. Duru OK, Li S, Jurkovitz C, Bakris G, Brown W, Chen SC, et al. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008;51:192–198
  29. Rao MV, Qiu Y, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008;51(Suppl 2):S30–S37
  30. Marcantoni C, Ma LJ, Federspiel C, Fogo AB. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int. 2002;62:172–180
  31. Hoy WE, Bertram JF, Denton RD, Zimanyi M, Samuel T, Hughson MD. Nephron number, glomerular volume, renal disease and hypertension. Curr Opin Nephrol Hypertens. 2008;17:258–265
  32. Gonzalez E, Gutierrez E, Morales E, Hernandez E, Andres A, Bello I, et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int. 2005;68:263–270
  33. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol. 2000;11:319–329
  34. Muntner P, He J, Vupputuri S, Coresh J, Batuman V. Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int. 2003;63:1044–1050
  35. Kim R, Hu H, Rotnitzky A, Bellinger D, Needleman H. Longitudinal relationship between dentin lead levels in childhood and bone lead levels in young adulthood. Arch Environ Health. 1996;51:375–382
  36. Coburn JW. An update on vitamin D as related to nephrology practice: 2003. Kidney Int Suppl. 2003;87:S125–S130
  37. Wartiovaara J, Ofverstedt LG, Khoshnoodi J, Zhang J, Makela E, Sandin S, et al. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest. 2004;114:1475–1483
  38. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99:342–348
  39. Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int. 2001;60:957–968
  40. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int. 2002;61:1475–1485
  41. Hara M, Yanagihara T, Kihara I. Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron. 2001;89:342–347
  42. Kriz W. Progressive renal failure—inability of podocytes to replicate and the consequences for development of glomerulosclerosis. Nephrol Dial Transplant. 1996;11:1738–1742
  43. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol. 2002;13:3005–3015
  44. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol. 2003;285:F40–F48
  45. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005;16:1733–1741
  46. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia. 1999;42:1341–1344
  47. Hara M, Yanagihara T, Kihara I. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schonlein-Henoch purpura nephritis. Clin J Am Soc Nephrol. 2007;2:231–238
  48. Wiggins JE, Goyal M, Sanden SK, Wharram BL, Shedden KA, Misek DE, et al. Podocyte hypertrophy, “adaptation,” and “decompensation” associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol. 2005;16:2953–2966
  49. Pabst R, Sterzel RB. Cell renewal of glomerular cell types in normal rats (An autoradiographic analysis). Kidney Int. 1983;24:626–631
  50. Wilson PD. Polycystic kidney disease. N Engl J Med. 2004;350:151–164
  51. Lanoix J, D'Agati V, Szabolcs M, Trudel M. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene. 1996;13:1153–1160
  52. Ito C, Yamamoto H, Furukawa Y, Takeda S, Akimoto T, Iimura O, et al. Role of cyclins in cAMP inhibition of glomerular mesangial cell proliferation. Clin Sci (Lond). 2004;107:81–87
  53. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13:806–816
  54. Pillebout E, Burtin M, Yuan HT, Briand P, Woolf AS, Friedlander G, et al. Proliferation and remodeling of the peritubular microcirculation after nephron reduction: association with the progression of renal lesions. Am J Pathol. 2001;159:547–560
  55. Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn AM, Claffey KP, Reilly M, et al. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol. 1995;147:1715–1727
  56. Kang DH, Johnson RJ. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens. 2003;12:43–49
  57. Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest. 1999;104:913–923
  58. Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol. 2001;159:599–608
  59. Bello-Reuss E, Holubec K, Rajaraman S. Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int. 2001;60:37–45
  60. Isbel NM, Hill PA, Foti R, Mu W, Hurst LA, Stambe C, et al. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int. 2001;60:614–625
  61. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001;12:1434–1447
  62. Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC. Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int. 1995;48:753–760
  63. Savill J. Regulation of glomerular cell number by apoptosis. Kidney Int. 1999;56:1216–1222
  64. Nishida M, Fujinaka H, Matsusaka T, Price J, Kon V, Fogo AB, et al. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest. 2002;110:1859–1868
  65. El-Koraie AF, Baddour NM, Adam AG, El Kashef EH, El Nahas AM. Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides. Kidney Int. 2001;60:167–172
  66. Li L, Huang L, Sung SS, Vergis AL, Rosin DL, Rose CE, et al. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int. 2008;
  67. Fan JM, Huang XR, Ng YY, Nikolic-Paterson DJ, Mu W, Atkins RC, et al. Interleukin-1 induces tubular epithelial-myofibroblast transdifferentiation through a transforming growth factor-beta1-dependent mechanism in vitro. Am J Kidney Dis. 2001;37:820–831
  68. Al-Awqati Q, Oliver JA. Stem cells in the kidney. Kidney Int. 2002;61:387–395
  69. van Goor H, van der Horst ML, Fidler V, Grond J. Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation. Lab Invest. 1992;66:564–571
  70. Lovett DH, Johnson RJ, Marti HP, Martin J, Davies M, Couser WG. Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am J Pathol. 1992;141:85–98
  71. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15:290–301
  72. Zhang G, Eddy AA. Urokinase and its receptors in chronic kidney disease. Front Biosci. 2008;13:5462–5478
  73. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int. 2006;69:1064–1072
  74. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002;13:2600–2610
  75. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int. 2002;61:1714–1728
  76. Taneda S, Hudkins KL, Topouzis S, Gilbertson DG, Ophascharoensuk V, Truong L, et al. Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury. J Am Soc Nephrol. 2003;14:2544–2555
  77. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66:1–9
  78. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol. 2003;81:355–363
  79. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577–584
  80. Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J. 2003;17:1576–1578
  81. Wang L, Kwak JH, Kim SI, He Y, Choi ME. Transforming grow`th factor-beta1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J Biol Chem. 2004;279:33213–33219
  82. Runyan CE, Schnaper HW, Poncelet AC. The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-beta1. J Biol Chem. 2004;279:2632–2639
  83. Runyan CE, Schnaper HW, Poncelet AC. Smad3 and PKCdelta mediate TGF-beta1-induced collagen I expression in human mesangial cells. Am J Physiol Renal Physiol. 2003;285:F413–F422
  84. Masszi A, Di Ciano C, Sirokmany G, Arthur WT, Rotstein OD, Wang J, et al. Central role for Rho in TGF-beta1-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition. Am J Physiol Renal Physiol. 2003;284:F911–F924
  85. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes. 2008;57:714–723
  86. Price PM. Diabetes: caught in the Akt?. Kidney Int. 2007;71:839–841
  87. Toyoda M, Suzuki D, Honma M, Uehara G, Sakai T, Umezono T, et al. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int. 2004;66:1107–1114
  88. Cattran DC. Cyclosporine in the treatment of idiopathic focal segmental glomerulosclerosis. Semin Nephrol. 2003;23:234–241
  89. Bhimma R, Adhikari M, Asharam K, Connolly C. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol. 2006;26:544–551
  90. Schnaper HW, Robson AM, Kopp JB. Nephrotic syndrome: minimal change nephropathy, focal segmental glomerulosclerosis and collapsing glomerulopathy. In:  Schrier RW editors. Diseases of the kidney and urinary tract. 8th ed.. Philadelphia: Lippincott Williams & Wilkins; 2006;p. 1585–1673
  91. Ardissino G, Testa S, Dacco V, Vigano S, Taioli E, Claris-Appiani A, et al. Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy (Data from the Ital Kid Project). Pediatr Nephrol. 2004;19:172–177
  92. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics. 2000;105:1242–1249
  93. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357:1601–1608
  94. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  95. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(Suppl 1):S1–S290
  96. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(Suppl):555–576
  97. Timio M, Venanzi S, Lolli S, Lippi G, Verdura C, Monarca C, et al. “Non-dipper” hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol. 1995;43:382–387
  98. Hilgers KF, Dotsch J, Rascher W, Mann JF. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?. Pediatr Nephrol. 2004;19:956–961
  99. Wuhl E, Mehls O, Schaefer F. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66:768–776
  100. Rodriguez M, Felsenfeld AJ. PTH, FGF-23 and early CKD. Nephrol Dial Transplant. 2008;23:3391–3393
  101. Lemire JM. Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol. 1995;53:599–602
  102. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229–238
  103. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68:2823–2828
  104. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66:753–760
  105. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004;15:2115–2124
  106. Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H, et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int. 2007;72:455–463
  107. Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol. 2007;117:64–74
  108. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis. 2005;45:2–14
  109. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int. 2002;61:1635–1645
  110. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
  111. Neale TJ, Ojha PP, Exner M, Poczewski H, Ruger B, Witztum JL, et al. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J Clin Invest. 1994;94:1577–1584
  112. Chan JC, Mahan JD, Trachtman H, Scheinman J, Flynn JT, Alon US, et al. Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study. Pediatr Nephrol. 2003;18:1015–1019
  113. Winbanks CE, Grimwood L, Gasser A, Darby IA, Hewitson TD, Becker GJ. Role of the phosphatidylinositol 3-kinase and mTOR pathways in the regulation of renal fibroblast function and differentiation. Int J Biochem Cell Biol. 2007;39:206–219
  114. Bakris GL. Protein kinase C-beta inhibition: a promise not yet fulfilled. Clin J Am Soc Nephrol. 2007;2:619–620
  115. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int. 2003;64:2009–2019
  116. Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant. 1997;12:2295–2300
  117. Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol. 2006;17:54–65
  118. Lan HY. Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci. 2008;13:4984–4992
  119. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl 3):S1–S201
  120. Andreoli SP, Brewer ED, Watkins S, Fivush B, Powe N, Shevchek J, et al. American Society of Pediatric Nephrology position paper on linking reimbursement to quality of care. J Am Soc Nephrol. 2005;16:2263–2269
  121. Abitbol CL, Warady BA, Massie MD, Baluarte HJ, Fleischman LE, Geary DF, et al. Linear growth and anthropometric and nutritional measurements in children with mild to moderate renal insufficiency: a report of the Growth Failure in Children with Renal Diseases Study. J Pediatr. 1990;116:S46–S54
  122. Mak RH, Cheung WW, Roberts CT. The growth hormone-insulin-like growth factor-I axis in chronic kidney disease. Growth Horm IGF Res. 2008;18:17–25
  123. Furth SL, Hwang W, Yang C, Neu AM, Fivush BA, Powe NR. Growth failure, risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol. 2002;17:450–455
  124. Fine RN, Ho M, Tejani A, Blethen S. Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease. J Pediatr. 2003;142:539–545
  125. Rosenbloom AL. Recombinant human insulin-like growth factor I (rhIGF-I) and rhIGF-I/rhIGF-binding-protein-3: new growth treatment options?. J Pediatr. 2007;150:7–11
  126. Fogo AB. New capillary growth: a contributor to regression of sclerosis?. Curr Opin Nephrol Hypertens. 2005;14:201–203
  127. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol. 2001;12:1448–1457
  128. Chen J, Park HC, Addabbo F, Ni J, Pelger E, Li H, et al. Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair. Kidney Int. 2008;74:879–889

PII: S0270-9295(09)00053-9

doi: 10.1016/j.semnephrol.2009.03.016

Seminars in Nephrology
Volume 29, Issue 4 , Pages 412-424 , July 2009

Article Tools

* Image Usage & Resolution